



PRESS RELEASE

Extension of subscription period for Visiomed Group crowdfunding bond issue, with subscription target already exceeded

Paris, August 16th, 2022

Visiomed Group (FR0013481835 – ALVMG), a group specializing in innovative healthcare technologies and services, today announces the extension of the subscription period for its crowdfunding bond issue until **11.59 p.m. on Friday, August 19th, 2022**.

The current amount subscribed via the [Equisafe Invest](#) platform has exceeded €3.3 million, well above the initial subscription target of €2.5 million.

As a reminder, these two-year bonds are redeemable at maturity at par and bear an annual coupon of 10.5% payable once a year.

Visiomed Group CEO Thomas Picquette said: *“We are extremely proud of this first ever crowdfunding bond issue carried out by a company listed on Euronext Growth Paris. We have decided to extend the subscription period by a few days to cater to certain identified investors requiring more time for bank procedures, thus honoring the trust they place in our Company.”*

All information and a link to the bond issue subscription form may be found on the [Equisafe Invest](#) website. Equisafe Invest is registered as a crowdfunding investment adviser (*Conseiller en Investissement Participatif*) under ORIAS.

[Equisafe Invest](#)

Disclaimer

This issue will not result in a Prospectus approved by the AMF.

Risk factors

The public's attention is drawn to the risk factors relating to the Company and its business, described in the 2021 Annual Financial Report available on the Company's website (www.visiomed.fr). The occurrence of some or all of these risks could have an adverse effect on the company's business, financial situation, results, development or prospects.

About VISIOMED GROUP

Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.

The Group now has two wholly-owned subsidiaries:

- **BewellConnect, created in 2014, pioneer in connected health and teleconsultation solutions**

BewellConnect offers an enriched technological universe, both in medical devices and software, making it possible to respond to all telehealth use cases: enriched and assisted teleconsultation, home telemonitoring, hospital monitoring, tele-expertise, teleassistance and tele-regulation.

BewellConnect's flagship product, VisioCheck, is the first telemedicine station weighing less than 300g for healthcare professionals, available in a case, station or modular health space.

BewellConnect is now deploying its solutions in France and abroad.

- **Smart Salem, the first digital medical analysis center accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates**

The Smart Salem offer is based on know-how in medical analysis, radiology and data analysis and processing to detect nearly 35 diseases in 7 minutes in a patient (in particular HIV, hepatitis and tuberculosis) by offering reliable results, readability and exceptional patient experience enabled by advanced artificial intelligence and virtual reality technologies.

Smart Salem's "Medical Fitness Assessment" offer resulting from this know-how thus makes it possible to obtain a residence or work visa in the space of 30 minutes compared to 10 to 15 days in historical health centers.

Smart Salem is a technological platform offering many growth opportunities, as shown by the opening of the second center in Dubai in September 2022 and the authorization received for the opening of a third center, planned to open in the first quarter of 2023.

Based in Paris, VISIOMED GROUP is listed on Euronext Growth (ALVMG). More information on visiomed.fr, smartsalem.ae and www.bewell-connect.com.



CONTACTS

Jérôme FABREGUETTES-LEIB
Investor Relations
visiomed@actus.fr
Phone: +33 1 53 67 36 78

Fatou-Kiné N'DIAYE
Financial Press Relations
fndiaye@actus.fr
Phone: +33 1 53 67 36 75

© Visiomed Group SA 2022. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.

Disclaimer

This press release contains statements that are not factual, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current views and assumptions of the Company's management. They involve known and unknown risks and uncertainties that could cause actual results, profitability and events to differ materially. In addition, VISIOMED GROUP, its shareholders and its respective affiliates, directors, officers, consultants and employees have not verified the accuracy of, and make no representations or warranties with respect to, any statistical information or forward-looking information contained in this press release that is derived from third party sources or industry publications. Such statistical data and forward-looking information is used in this release for informational purposes only.